Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

NCT05524974 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

203

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Gastric Cancer

Interventions

DRUG: Camrelizumab
DRUG: Oxaliplatin
DRUG: S1
DRUG: Apatinib Mesylate
DRUG: Nab paclitaxel

Sponsor

Fujian Medical University